Market research
PJT.F Pluristem Therapeutics Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- 8.92
- Dividend yield
- 0.0%
- Beta
- 1.91
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 31M
- P/E ratio
- Not available
- Analyst target
- 8.92
- Dividend yield
- 0.0%
- Beta
- 1.91
About
About Pluristem Therapeutics Inc
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PJT.F discussion.
5 years, 4 months ago
Pluristem Therapeutics Inc is currently in a long term downtrend where the price is trading 45.4% below its 200 day moving average.
From a valuation standpoint, the stock is 391.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 6450.2.
Pluristem Therapeutics Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 97.1% to $-13M since the same quarter in the previous year.
Finally, its free cash flow fell by 25.1% to $-8M since the same quarter in the previous year.
Based on the above factors, Pluristem Therapeutics Inc gets an overall score of 0/5.